Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Co-activation of WT1 and AP-1 proteins on WT1 gene promoter to induce WT1 gene expression in K562 cells.

Anuchapreeda S, Rungrojsakul M, Tima S, Chiampanichayakul S, Krig SR.

Cell Signal. 2019 Jan;53:339-347. doi: 10.1016/j.cellsig.2018.11.001. Epub 2018 Nov 3.

PMID:
30395942
2.

Coordination of m(6)A mRNA Methylation and Gene Transcription by ZFP217 Regulates Pluripotency and Reprogramming.

Aguilo F, Zhang F, Sancho A, Fidalgo M, Di Cecilia S, Vashisht A, Lee DF, Chen CH, Rengasamy M, Andino B, Jahouh F, Roman A, Krig SR, Wang R, Zhang W, Wohlschlegel JA, Wang J, Walsh MJ.

Cell Stem Cell. 2015 Dec 3;17(6):689-704. doi: 10.1016/j.stem.2015.09.005. Epub 2015 Oct 29.

3.

Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.

Frietze S, O'Geen H, Littlepage LE, Simion C, Sweeney CA, Farnham PJ, Krig SR.

BMC Genomics. 2014 Jun 24;15:520. doi: 10.1186/1471-2164-15-520.

4.

The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z.

Cancer Discov. 2012 Jul;2(7):638-51. doi: 10.1158/2159-8290.CD-12-0093. Epub 2012 May 10.

5.

Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer.

Krig SR, Frietze S, Simion C, Miller JK, Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, Carraway KL 3rd, Sweeney C.

Mol Cancer Res. 2011 Oct;9(10):1406-17. doi: 10.1158/1541-7786.MCR-11-0227. Epub 2011 Aug 5.

6.

Inhibitory mechanism of pure curcumin on Wilms' tumor 1 (WT1) gene expression through the PKCα signaling pathway in leukemic K562 cells.

Semsri S, Krig SR, Kotelawala L, Sweeney CA, Anuchapreeda S.

FEBS Lett. 2011 Jul 21;585(14):2235-42. doi: 10.1016/j.febslet.2011.05.043. Epub 2011 Jun 7.

7.

ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.

Krig SR, Miller JK, Frietze S, Beckett LA, Neve RM, Farnham PJ, Yaswen PI, Sweeney CA.

Oncogene. 2010 Oct 7;29(40):5500-10. doi: 10.1038/onc.2010.289. Epub 2010 Jul 26.

8.

N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor.

Cotterman R, Jin VX, Krig SR, Lemen JM, Wey A, Farnham PJ, Knoepfler PS.

Cancer Res. 2008 Dec 1;68(23):9654-62. doi: 10.1158/0008-5472.CAN-08-1961.

9.

Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays.

Krig SR, Jin VX, Bieda MC, O'Geen H, Yaswen P, Green R, Farnham PJ.

J Biol Chem. 2007 Mar 30;282(13):9703-12. Epub 2007 Jan 26.

10.

Suz12 binds to silenced regions of the genome in a cell-type-specific manner.

Squazzo SL, O'Geen H, Komashko VM, Krig SR, Jin VX, Jang SW, Margueron R, Reinberg D, Green R, Farnham PJ.

Genome Res. 2006 Jul;16(7):890-900. Epub 2006 Jun 2.

11.

Gene-specific TCDD suppression of RARalpha- and RXR-mediated induction of tissue transglutaminase.

Krig SR, Chandraratna RA, Chang MM, Wu R, Rice RH.

Toxicol Sci. 2002 Jul;68(1):102-8.

PMID:
12075115
12.

Supplemental Content

Support Center